Published in major journals, first or last author from Oslo University Hospital.
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
JAMA Neurol (in press)
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Lancet Haematol (in press)
Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Eur Urol (in press)